M.D. Anderson Cancer Center: Leukemia trials

The registry lists 302 Leukemia studies with M.D. Anderson Cancer Center as lead sponsor. 5 are open to participants now and 169 have results posted.

Early Phase 1 1Phase 1 121Phase 2 201Phase 3 13No phase 26(a study in two phases counts in both)

Studies

Page 2 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedNCT00941928Phase 2Results posted
• Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic LeukemiaCompletedNCT00940342Phase 2Results posted
• Pharmacokinetics of Posaconazole Prophylaxis in Acute LeukemiaCompletedNCT00936117Phase 2Results posted
• Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) SalvageCompletedNCT00905034Phase 2Results posted
• Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00899431Phase 2Results posted
• Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia SalvageCompletedNCT00890656Phase 2Results posted
• Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)CompletedNCT00887068Phase 3Results posted
• Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)CompletedNCT00882102Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted
• Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk MalignanciesCompletedNCT00857389Phase 2Results posted
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and ThymoglobulinCompletedNCT00822770Phase 1/2Results posted
• Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)CompletedNCT00813124Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Rituximab - High Dose FrontlineCompletedNCT00794820Phase 2Results posted
• A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing FatigueCompletedNCT00792077Phase 2Results posted
• Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
• Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00778375Phase 2Results posted
• Alemtuzumab + Rituximab Consolidation in CLLTerminatedNCT00771602Phase 2Results posted
• Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00759798Phase 2Results posted
• Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaCompletedNCT00759603Phase 2Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic LeukemiaCompletedNCT00671658Phase 2Results posted
• Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00656617Phase 2Results posted
• A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDSCompletedNCT00656448Phase 3Results posted
• Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual DiseaseCompletedNCT00632359Phase 2Results posted
• Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00569010Phase 1/2Results posted
• Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)CompletedNCT00542971Phase 1/2Results posted
• Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and OlderCompletedNCT00535873Phase 2Results posted
• CFAR Study in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00525603Phase 2Results posted
• Etanercept (Enbrel) for Juvenile Myelomonocytic LeukemiaTerminatedNCT00509600Phase 2Results posted
• Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMTCompletedNCT00506922Phase 1/2Results posted
• Erwinase Study in Patients With Acute Lymphoblastic LeukemiaCompletedNCT00506597Not applicableResults posted
• Busulfan and Fludarabine in Patients With AML and MDSCompletedNCT00502905Phase 2Results posted
• Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)TerminatedNCT00500240Phase 3Results posted
• Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsTerminatedNCT00499889Phase 2Results posted
• Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) PatientsCompletedNCT00493181Phase 2Results posted
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT00480987Phase 1/2Results posted
• Thymoglobulin and Total Lymphoid Irradiation for Hematologic MalignanciesCompletedNCT00476229Not applicableResults posted
• Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and LeukemiasCompletedNCT00472849Phase 1/2Results posted
• IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00469144Phase 3Results posted
• Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid LeukemiaCompletedNCT00469014Phase 2Results posted
• A Study of Actonel for the Prevention of Bone LossCompletedNCT00452439Phase 3Results posted
• Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLLCompletedNCT00452374Phase 1/2Results posted
• Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic LeukemiaCompletedNCT00427791Phase 2Results posted
• Cellular Therapy With Cord Blood CellsCompletedNCT00427557Phase 2Results posted
• Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)CompletedNCT00422591Phase 2Results posted
• TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsTerminatedNCT00415909Phase 2Results posted
• Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)TerminatedNCT00415857Phase 2Results posted
• Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)CompletedNCT00414310Phase 2Results posted
• 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic LeukemiaTerminatedNCT00413478Phase 2Results posted
• All-trans Retinoic Acid, and Arsenic +/- IdarubicinCompletedNCT00413166Phase 2Results posted
• Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia PatientsCompletedNCT00412243Phase 1/2Results posted
• Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)CompletedNCT00398983Phase 2/3Results posted
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
• Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsCompletedNCT00382590Phase 2Results posted
• FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00381004Phase 2Results posted
• Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)CompletedNCT00364286Phase 2Results posted
• Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00360672Phase 2Results posted
• Phase II 5-Azacytidine Plus VPA Plus ATRACompletedNCT00326170Phase 2Results posted
• Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia PatientsCompletedNCT00323557Phase 2Results posted
• Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual DiseaseCompletedNCT00267085Phase 2Results posted
• Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT00267059Phase 2Results posted
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
• FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 YearsCompletedNCT00254410Phase 2Results posted
• Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)CompletedNCT00129740Phase 2Results posted
• Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).CompletedNCT00088218Phase 2Results posted
• Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
• Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
• Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesCompletedNCT00048737Phase 1/2Results posted
• Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant DiseasesCompletedNCT00038857Phase 2Results posted
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
• Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTerminatedNCT00038649Phase 2Results posted
• Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00038610Phase 2Results posted
• Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual DiseaseWithdrawnNCT06522373Phase 1
• A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid LeukemiaWithdrawnNCT06113289Phase 1/2
• Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic LeukemiaWithdrawnNCT06085638Phase 1/2
• A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineTerminatedNCT06021600Phase 1
• A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT05961696Phase 1
• STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1
• A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedNCT05268003Phase 2
• Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or DexamethasoneCompletedNCT05049785Early Phase 1
• Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedNCT05030675Phase 1
• Tegavivint for the Treatment of Relapsed or Refractory LeukemiaActive, not recruitingNCT04874480Phase 1
• Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
• Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary CaregiversActive, not recruitingNCT04090619
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
• PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT04022785Phase 1
• Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
• Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK InhibitorWithdrawnNCT03884972Phase 1
• TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid LeukemiaWithdrawnNCT03752138Phase 1
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT03207542Phase 2
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid LeukemiaTerminatedNCT03126864Phase 1
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2
• Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1